Condition
PSMA
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
Early P 1 (2)
Trial Status
Recruiting3
Unknown2
Not Yet Recruiting1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07639801Not ApplicableNot Yet Recruiting
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
NCT06419348Early Phase 1Recruiting
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
NCT06387381Early Phase 1RecruitingPrimary
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
NCT06320223Recruiting
PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
NCT05822726Not ApplicableUnknown
The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer
NCT05596851Unknown
Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy.
Showing all 6 trials